Comparison of Combined Transcatheter Arterial Chemoembolization and CT-guided Radiofrequency Ablation with Surgical Resection in Patients with Hepatocellular Carcinoma Within the Up-to-seven Criteria: A Multicenter Case-matched Study

Overview

Journal J Cancer

Specialty Oncology

Date 2017 Nov 21

PMID 29151935

Citations 20

Authors

Tao Pan

Lu-Wen Mu

Chun Wu

Xi-Qun Wu

Qian-Kun Xie

Xi-Shan Li

Ning Lyu

Shao-Long Li

Hai-Jing Deng

Zai-Bo Jiang

Ai-Hua Lin

Ming Zhao

Affiliations

Soon will be listed here.

Abstract

We compared the efficacy of transcatheter arterial chemoembolization (TACE) in combination with CT-guided radiofrequency ablation (RFA) with that of surgical resection (SR) in patients with hepatocellular carcinoma (HCC) within the up-to-seven criteria. From January 2004 to December 2014, 420 multicenter consecutive patients with HCC who conformed to the up-to-seven criteria and initially received either TACE plus CT-guided RFA (TACE-RFA) or SR were enrolled. A matched cohort composed of 206 patients was selected after adjustment with propensity score matching. The overall survival (OS) of each patient was calculated with the Kaplan-Meier method and compared by the log-rank test. The median OS and 1-, 3-, and 5-year survival rates were 56.0 months, 96.1%, 76.7% and 41.3% in the TACE-RFA group and 58.0 months, 96.1%, 86.4% and 46.2% in the SR group, respectively. There was no significant difference in OS between the two groups ( = 0.138). For patients with HCC beyond the Milan criteria, TACE-RFA provided a longer median OS than SR (52.0 vs 45.0 months, = 0.023). Treatment by TACE-RFA conferred an OS rate comparable with that of SR in patients within the up-to-seven criteria. For patients with HCC between the Milan and the up-to-seven criteria, TACE-RFA might be superior to SR for survival prolongation.

Citing Articles

Survival Benefits of Transarterial Chemoembolization Plus Ablation Therapy in Patients With Intermediate or Advanced Hepatocellular Carcinoma: A Propensity Score Matching Study.

Dai J, Ding Y, Zheng Q, Zhao G, Zou L, Zhao J Cancer Manag Res. 2025; 17:483-497.

PMID: 40060703 PMC: 11890005. DOI: 10.2147/CMAR.S511364.

Frontline evaluation: Atezolizumab-bevacizumab versus lenvatinib for BCLC stage B hepatocellular carcinoma exceeding the up-to-seven criteria.

Kimura M, Nishikawa K, Imamura J, Kimura K Cancer Med. 2024; 13(18):e70217.

PMID: 39300938 PMC: 11413408. DOI: 10.1002/cam4.70217.

Transarterial chemoembolization with insertion of radioactive seeds for hepatocellular carcinoma.

Wang Y, Zhang W, Bao L, Lu Y, Hong J Wideochir Inne Tech Maloinwazyjne. 2024; 18(4):645-654.

PMID: 38239583 PMC: 10793153. DOI: 10.5114/wiitm.2023.131539.

PIVKA-II combined with tumor burden score to predict long-term outcomes of AFP-negative hepatocellular carcinoma patients after liver resection.

Qiu Z, Wu Y, Qi W, Li C Cancer Med. 2023; 13(1):e6835.

PMID: 38130028 PMC: 10807584. DOI: 10.1002/cam4.6835.

Improved clinical outcomes in advanced hepatocellular carcinoma treated with transarterial chemoembolization plus atezolizumab and bevacizumab: a bicentric retrospective study.

Cao F, Shi C, Zhang G, Luo J, Zheng J, Hao W BMC Cancer. 2023; 23(1):873.

PMID: 37718456 PMC: 10506240. DOI: 10.1186/s12885-023-11389-x.

References

Bruix J, Reig M, Sherman M . Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. Gastroenterology. 2016; 150(4):835-53. DOI: 10.1053/j.gastro.2015.12.041. View

Bruix J, Sherman M . Management of hepatocellular carcinoma: an update. Hepatology. 2011; 53(3):1020-2. PMC: 3084991. DOI: 10.1002/hep.24199. View

Vivarelli M, Guglielmi A, Ruzzenente A, Cucchetti A, Bellusci R, Cordiano C . Surgical resection versus percutaneous radiofrequency ablation in the treatment of hepatocellular carcinoma on cirrhotic liver. Ann Surg. 2004; 240(1):102-7. PMC: 1356381. DOI: 10.1097/01.sla.0000129672.51886.44. View

Seror O, Nkontchou G, Nault J, Rabahi Y, Nahon P, Ganne-Carrie N . Hepatocellular Carcinoma within Milan Criteria: No-Touch Multibipolar Radiofrequency Ablation for Treatment-Long-term Results. Radiology. 2016; 280(2):611-21. DOI: 10.1148/radiol.2016150743. View

Yamakado K, Nakatsuka A, Takaki H, Yokoi H, Usui M, Sakurai H . Early-stage hepatocellular carcinoma: radiofrequency ablation combined with chemoembolization versus hepatectomy. Radiology. 2008; 247(1):260-6. DOI: 10.1148/radiol.2471070818. View

Wada H, Eguchi H, Noda T, Ogawa H, Yamada D, Tomimaru Y . Selection criteria for hepatic resection in intermediate-stage (BCLC stage B) multiple hepatocellular carcinoma. Surgery. 2016; 160(5):1227-1235. DOI: 10.1016/j.surg.2016.05.023. View

Sacks D, McClenny T, Cardella J, Lewis C . Society of Interventional Radiology clinical practice guidelines. J Vasc Interv Radiol. 2003; 14(9 Pt 2):S199-202. DOI: 10.1097/01.rvi.0000094584.83406.3e. View

Bolondi L, Burroughs A, Dufour J, Galle P, Mazzaferro V, Piscaglia F . Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis. 2013; 32(4):348-59. DOI: 10.1055/s-0032-1329906. View

Zhao M, Wang J, Pan C, Li W, Huang Z, Zhang L . CT-guided radiofrequency ablation after with transarterial chemoembolization in treating unresectable hepatocellular carcinoma with long overall survival improvement. Eur J Radiol. 2012; 81(10):2717-25. DOI: 10.1016/j.ejrad.2011.10.023. View

10.

Pan T, Xie Q, Lv N, Li X, Mu L, Wu P . Percutaneous CT-guided Radiofrequency Ablation for Lymph Node Oligometastases from Hepatocellular Carcinoma: A Propensity Score-matching Analysis. Radiology. 2016; 282(1):259-270. DOI: 10.1148/radiol.2016151807. View

11.

Peng Z, Zhang Y, Chen M, Xu L, Liang H, Lin X . Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J Clin Oncol. 2012; 31(4):426-32. DOI: 10.1200/JCO.2012.42.9936. View

12.

Shibata T, Isoda H, Hirokawa Y, Arizono S, Shimada K, Togashi K . Small hepatocellular carcinoma: is radiofrequency ablation combined with transcatheter arterial chemoembolization more effective than radiofrequency ablation alone for treatment?. Radiology. 2009; 252(3):905-13. DOI: 10.1148/radiol.2523081676. View

13.

Hung H, Chiou Y, Hsia C, Su C, Chou Y, Chiang J . Survival rates are comparable after radiofrequency ablation or surgery in patients with small hepatocellular carcinomas. Clin Gastroenterol Hepatol. 2010; 9(1):79-86. DOI: 10.1016/j.cgh.2010.08.018. View

14.

Abu-Hilal M, Primrose J, Casaril A, McPhail M, Pearce N, Nicoli N . Surgical resection versus radiofrequency ablation in the treatment of small unifocal hepatocellular carcinoma. J Gastrointest Surg. 2008; 12(9):1521-6. DOI: 10.1007/s11605-008-0553-4. View

15.

Makuuchi M, Hasegawa H, Yamazaki S . Ultrasonically guided subsegmentectomy. Surg Gynecol Obstet. 1985; 161(4):346-50. View

16.

Morimoto M, Numata K, Kondou M, Nozaki A, Morita S, Tanaka K . Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization. Cancer. 2010; 116(23):5452-60. DOI: 10.1002/cncr.25314. View

17.

Torre L, Bray F, Siegel R, Ferlay J, Lortet-Tieulent J, Jemal A . Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65(2):87-108. DOI: 10.3322/caac.21262. View

18.

Peng Z, Lin X, Zhang Y, Liang H, Guo R, Shi M . Radiofrequency ablation versus hepatic resection for the treatment of hepatocellular carcinomas 2 cm or smaller: a retrospective comparative study. Radiology. 2012; 262(3):1022-33. DOI: 10.1148/radiol.11110817. View

19.

Kim J, Kim J, Won H, Shin Y, Yoon H, Sung K . Hepatocellular carcinomas 2-3 cm in diameter: transarterial chemoembolization plus radiofrequency ablation vs. radiofrequency ablation alone. Eur J Radiol. 2011; 81(3):e189-93. DOI: 10.1016/j.ejrad.2011.01.122. View

20.

Koh Y, Choi J, Kim H, Kim M . Computed tomographic-guided radiofrequency ablation of recurrent or residual hepatocellular carcinomas around retained iodized oil after transarterial chemoembolization. Korean J Radiol. 2013; 14(5):733-42. PMC: 3772252. DOI: 10.3348/kjr.2013.14.5.733. View